Over the past decade, significant progress was made in the treatment of patients with multiple myeloma (MM). Nevertheless, research efforts continue in an attempt to develop treatment options with novel mechanisms of action that have higher efficacy, can evade resistance to prior lines of treatment and are well tolerated. As the B-cell maturation antigen (BCMA) is preferentially expressed by mature B-lymphocytes and is overexpressed in MM patients, it provides an interesting therapeutic target in MM. Thus far, three treatment modalities have been developed for BCMA targeting; bispecific antibody constructs, antibody-drug conjugates and chimeric antigen receptor (CAR) T-cell therapy, each with its own advantages and challenges. This review provides an overview of the (preliminary) clinical data that were generated with these different treatment modalities.
(BELG J HEMATOL 2020;11(8):387-97)